MOA Life Plus Co. Ltd. (KOSDAQ:142760)
South Korea · Delayed Price · Currency is KRW 1,747.00
-8.00 (-0.46%)
At close: Jan 26, 2026
MOA Life Plus Revenue
MOA Life Plus had revenue of 1.18B KRW in the quarter ending September 30, 2025, a decrease of -66.64%. This brings the company's revenue in the last twelve months to 9.80B, down -42.62% year-over-year. In the year 2024, MOA Life Plus had annual revenue of 15.63B, down -14.34%.
Revenue (ttm)
9.80B
Revenue Growth
-42.62%
P/S Ratio
6.85
Revenue / Employee
233.33M
Employees
42
Market Cap
67.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.63B | -2.62B | -14.34% |
| Dec 31, 2023 | 18.25B | -3.76B | -17.08% |
| Dec 31, 2022 | 22.00B | -79.17B | -78.25% |
| Dec 31, 2021 | 101.17B | 20.72B | 25.75% |
| Dec 31, 2020 | 80.45B | 7.58B | 10.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 31.12B |
| Naturalendo Tech | 21.87B |
| Ark Solutions | 21.50B |
| PanGen Biotech | 15.27B |
| NGeneBio | 9.98B |
| HLB Pep | 4.89B |
| EyeGene | 4.10B |
| Quratis | 2.28B |